Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Non-Alcoholic Steatohepatitis (NASH) Market Size, Value And Growth Trajectory Through 2030
The non-alcoholic steatohepatitis (nash) market has witnessed significant growth in recent years. This market is projected to expand from $6.06 billion in 2025 to $8.04 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 32.7%. The market’s historical growth can be linked to factors such as limited awareness concerning nash, a scarcity of effective treatment solutions, a reliance on lifestyle adjustments, the widespread occurrence of metabolic disorders, and a disjointed market environment.
The non-alcoholic steatohepatitis (nash) market is projected for rapid expansion over the coming years. This market is set to reach $24.32 billion by 2030, achieving a compound annual growth rate (CAGR) of 31.9%. Factors contributing to this anticipated growth include advancements in targeted therapies, greater healthcare spending, increasing use of non-invasive diagnostics, expanding pharmaceutical pipelines, and a surge in R&D collaborations. Key trends for the forecast period encompass the increasing prevalence of obesity and type 2 diabetes, the development of non-invasive diagnostic tools, intensified research into liver fibrosis therapies, an uptick in personalized and targeted drug treatments, and the widening reach of hospital and retail pharmacy networks.
Get A Free Sample Report With In-Depth Market Insights:
Non-Alcoholic Steatohepatitis (NASH) Market Expansion Drivers: What’s Shaping Future Growth?
The increasing incidence of obesity is fueling the demand within the non-alcoholic steatohepatitis (NASH) market in the future. Obesity is defined as an abnormal or excessive accumulation of fat that presents a health risk, alongside a body weight exceeding what is considered healthy or standard for an individual’s height. With non-alcoholic fatty liver disease becoming more common due to the growing obesity pandemic, NASH is anticipated to emerge as the primary cause of severe liver disease in the coming decades, consequently boosting the necessity for NASH therapies and associated medications. For example, data from May 2025 by the Government Digital Service, a UK government organization, indicates that from 2023 to 2024, the proportion of adults who were overweight (including obese) was greater in men (69.7%) compared to women (59.2%), whereas the proportion of obese adults was higher among women (26.9%) than men (26.2%). Consequently, the escalation in obesity cases is expected to propel the expansion of the non-alcoholic steatohepatitis (NASH) market.
Non-Alcoholic Steatohepatitis (NASH) Market Breakdown By Product Type And Application
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Dosage Form: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
Non-Alcoholic Steatohepatitis (NASH) Market Strategic Trends: What Defines The Next Growth Phase?
Companies active in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists. These compounds are specifically developed to enhance liver metabolism, reduce liver fat accumulation, and improve liver function. THR-beta agonists operate by selectively activating the thyroid hormone receptor-beta subtype, a critical receptor involved in regulating metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US regulatory body, granted approval to Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist, as the initial treatment for adults with noncirrhotic NASH exhibiting moderate to advanced liver scarring (fibrosis). By specifically engaging the THR-beta receptor, Rezdiffra aids in regulating lipid metabolism, leading to a decrease in intrahepatic triglycerides and overall liver fat accumulation.
Non-Alcoholic Steatohepatitis (NASH) Market Company Landscape And Competitive Strategy
Major companies operating in the non-alcoholic steatohepatitis (nash) market are NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens
View The Full Non-Alcoholic Steatohepatitis (NASH) Market Report:
Non-Alcoholic Steatohepatitis (NASH) Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2025. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
